MARKET

EVLO

EVLO

Evelo Biosciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.91
+0.37
+3.21%
After Hours: 11.91 0 0.00% 16:41 05/18 EDT
OPEN
11.62
PREV CLOSE
11.54
HIGH
12.48
LOW
11.60
VOLUME
105.05K
TURNOVER
--
52 WEEK HIGH
19.93
52 WEEK LOW
3.550
MARKET CAP
635.68M
P/E (TTM)
-5.2783
1D
5D
1M
3M
1Y
5Y
Evelo up 7% after posting preclinical data on anti-inflammatory candidate
Shares of Evelo Biosciences (EVLO) shot up 7% in morning trading after the company announced positive preclinical data on EDP2939 for inflammatory diseases.EDP2939, an extracellular vesicle candidate, showed broad- resolution of inflammation
Seekingalpha · 5d ago
Evelo Biosciences Presents New Preclinical Data for Extracellular Vesicle Anti-inflammatory Product Candidate EDP2939 at the American Association of Immunologists Meeting
-On-track to initiate clinical development of EDP2939 in 2022-
GlobeNewswire · 5d ago
52 Biggest Movers From Yesterday
Gainers Regional Health Properties, Inc. (NYSE: RHE) shares climbed 102.5% to close at $14.62 on Monday after jumping 38% on Friday.
Benzinga · 05/04 09:00
12 Health Care Stocks Moving In Monday's Intraday Session
 
Benzinga · 05/03 17:04
OCGN, AHT, NVAX and VXRT among midday movers
Gainers: Precipio (PRPO) +102%.Regional Health Properties (RHE) +94%.American Shared Hospital Services (AMS) +33%.Brooklyn ImmunoTherapeutics (BTX) +26%.Scully Royalty (SRL) +25%.Ocugen (OCGN) +23%.Top Ships (TOPS) +23%.Rezolute (RZLT) +20%.Milestone Scien...
Seekingalpha · 05/03 16:38
32 Stocks Moving In Monday's Mid-Day Session
Gainers Regional Health Properties, Inc. (NYSE: RHE) shares jumped 99.7% to $14.42 after jumping 38% on Friday.
Benzinga · 05/03 16:00
Regional Health Properties, Brooklyn ImmunoTherapeutics leads healthcare gainers; Vaxart, Regulus Therapeutics among major losers
Gainers: Regional Health Properties (RHE) +92%, Brooklyn ImmunoTherapeutics (BTX) +32%, Precipio PRPO +30%, Rezolute (RZLT) +28%, Milestone Scientific (MLSS) +15%.Losers: Vaxart VXRT -18%, Regulus Therapeutics RGLS -18%, Humanigen (HGEN) -12%, Evelo Biosci...
Seekingalpha · 05/03 15:00
--Morgan Stanley Adjusts Evelo Biosciences PT to $13 From $14, Maintains Equal Weight Rating
MT Newswires · 05/03 11:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EVLO. Analyze the recent business situations of Evelo Biosciences through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EVLO stock price target is 21.40 with a high estimate of 36.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 75
Institutional Holdings: 46.20M
% Owned: 86.55%
Shares Outstanding: 53.37M
TypeInstitutionsShares
Increased
30
3.00M
New
14
2.19M
Decreased
11
43.40K
Sold Out
2
15.26K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.07%
Key Executives
Chairman/Director
David Epstein
Chief Executive Officer/Director
Simba Gill
President/Chief Executive Officer/Chief Financial Officer/Treasurer/Director
Balkrishan Gill
Chief Accounting Officer/Controller
Xiaoli Liu
Chief Scientific Officer
Mark Bodmer
General Counsel/Secretary
Daniel Char
Other
Duncan McHale
Other
Jonathan Zung
Director
John Hohneker
Director
Julie McHugh
Independent Director
Juan Andres
Independent Director
Lord Ara Darzi
Independent Director
Theodose Melas-Kyriazi
Independent Director
David Perry
Independent Director
Nancy Simonian
No Data
About EVLO
Evelo Biosciences, Inc. is engaged in developing therapies designed to act on gut-body network. The Company develops monoclonal microbes that are orally-delivered compositions of specific strains of naturally occurring microbes derived from a single clone. Its principal product candidates include EDP1066, EDP1815, and EDP1503 that are in the pre-clinical development stage. EDP1066 and EDP1815 are monoclonal microbial product candidates that are developed to treat inflammatory diseases that include psoriasis, atopic dermatitis, rheumatoid arthritis, and ulcerative colitis. EDP1503 is the Company's product candidate developed under oncology portfolio to treat diseases, such as colorectal cancer, renal cell carcinoma, and melanoma among others.

Webull offers kinds of Evelo Biosciences Inc stock information, including NASDAQ:EVLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVLO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EVLO stock methods without spending real money on the virtual paper trading platform.